4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program [Yahoo! Finance]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Yahoo! Finance
NEWTON, Mass., April 14, 2026 BUSINESS WIRE 4D Path , a company dedicated to personalizing cancer care through a novel, physics-informed approach to predicting tumor response to therapy, today announced a collaboration with Daiichi Sankyo (TSE: 4568) to develop next-generation predictive biomarkers in an antibody drug conjugate (ADC) clinical development program. ADCs are among the most promising therapeutic classes in oncology, yet there remains a significant unmet need for scalable biomarkers that predict which patients are most likely to benefit from increasingly complex regimens and combination therapies. This collaboration brings together 4D Path's ability to compute biologically grounded, physics-informed treatment predictive biomarkers from routine pathology specimens with the ADC innovation leadership of Daiichi Sankyo. Under the collaboration, 4D Path will apply its proprietary Q-Plasia OncoReader™ (QPOR™) platform to standard Hematoxylin and Eosin (H&E)-stained tumor bi
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions [Yahoo! Finance]Yahoo! Finance
- Merck's Priority Review Cancer Drug Adds To Undervalued Growth Story [Yahoo! Finance]Yahoo! Finance
- Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies [Yahoo! Finance]Yahoo! Finance
- Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery TechnologiesPR Newswire
- Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase [Yahoo! Finance]Yahoo! Finance